Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200

March 12, 2024 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Australian company Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease. …

Subscribe now to continue reading.

Latest Video

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race
November 11, 2025 - Latest News
CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'
November 11, 2025 - Latest News
New Zealand accelerates medicines reform with major regulatory changes
November 12, 2025 - Latest News
Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'
November 11, 2025 - Latest News
'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'
November 11, 2025 - Latest News

Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

New Zealand accelerates medicines reform with major regulatory changes

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

New Stories

Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments

Sanofi building an AI-literate organisation through expectations, over experiments

Prospection says data access and leadership are critical to unlock AI’s potential in healthcare

The four 'H' words that can help drive the adoption of AI in health

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease

Sign In

Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

New Zealand accelerates medicines reform with major regulatory changes

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

Follow Us

New Stories

Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments

Sanofi building an AI-literate organisation through expectations, over experiments

Prospection says data access and leadership are critical to unlock AI’s potential in healthcare

The four 'H' words that can help drive the adoption of AI in health

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease